Title
Category
Credits
Event date
Cost
  • Disease management
  • Palliative care and hospice
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will discuss the role of palliative care in a primary care setting and the impact it has on quality of life for patients and their families. Patients who can benefit from palliative care will be identified and strategies to engage patients in the palliative-care discussion will also be reviewed, along with resources for both patients and providers that require a higher level of care.
  • Pediatrics
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity is designed to introduce the basic concepts of providing services to specialized children and youth populations. It will discuss the importance of interdisciplinary collaboration, including the role of child welfare workers and juvenile justice workers within those interdisciplinary teams. A basic overview of consent laws and required documentation for children in state custody will also be covered, along with state compliance regulations for professionals working with children involved in the child welfare and juvenile justice system.
  • Disease management
  • Vision
  • 1.00 AMA - Physicians
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
This activity will provide a current update to participants’ comprehensive knowledge and understanding of various contact lens options for patients with common diagnoses requiring medically necessary contact lenses. This session will delve into the tool chest of contact lens solutions, including standard rigid gas permeable (RGP) lens designs, reverse geometry RGPs, hybrids and scleral lenses. Participants will explore the anatomy of contact lenses, specific designs and applications for conditions such as keratoconus and irregular corneas. The activity will also cover the advantages and considerations associated with each lens type, patient experiences and advancements in scleral lens designs.
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will examine the scope, impact, key statistics and factors contributing to the opioid crisis and highlight the current recommended opioid prescribing guidelines, their challenges and the role of state prescription drug monitoring programs (PDMP). Strategies to aid in implementing the opioid prescribing guidelines and to mitigate the opioid crisis will also be discussed.
  • Behavioral health
  • Pediatrics
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss anxiety in the pediatric population, off-label use of medications for anxiety, and the “black box warning,” which warns the public of serious, permanent, and possibly fatal side effects caused by that medication. A treatment plan for a medication-naïve and a refractory, or treatment-resistant, patient with anxiety will also be highlighted.
  • Disease management
  • Wellness
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will discuss how to effectively assess for obesity and provide nonsurgical management interventions through helping patients commit to lifestyle changes and the use of pharmacotherapies.
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.
  • Behavioral health
  • Pediatrics
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will highlight the side effects of medications and drug interactions in treating depression and will discuss screening options for suicidality and how to create a basic safety plan.
  • Behavioral health
  • Disease management
  • Palliative care and hospice
  • 2.00 AMA - Physicians
  • 2.00 ANCC - Nurses
  • 2.00 Attendance - General Attendance
$0.00
Activity descriptionConversations that provide patients who have serious and life-threatening illnesses with the opportunity to make informed choices reflecting their goals, values and care preferences are a critical part of their care. These discussions can help ensure that seriously ill patients receive care that is consistent with their wishes and provide guidance to enhance family well-being and improve the patient’s quality of life.
  • Disease management
  • Vision
  • 1.00 AMA - Physicians
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
This activity will explore updated approaches to the management of glaucoma—the “silent thief of sight” that affects an estimated 3 million Americans. It will examine the latest evidence from recent studies on minimally invasive glaucoma surgery (MIGS) procedures and discuss comparative data on more invasive surgical techniques such as trabeculectomy and tube shunt surgery. Patient cases will be introduced to enhance participants’ understanding of the glaucoma treatment process. In addition, potential future innovations in glaucoma treatment will be discussed.

Pages